Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...

Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with an inflammatory skin disease in a ...

Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock ...

Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. | It was a busy day for Sanofi and ...

Eleven months after sustaining a rejection from the FDA for Dupixent to treat chronic spontaneous urticaria (CSU), Sanofi and ...

The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster ...

The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to include add-on maintenance treatment of adolescent patients aged 12 to 17 years with inadequately ...

Following an FDA rejection last year, the partners plan to resubmit their application for approval of Dupixent in chronic ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...